Nonclinical factors are more likely to drive discontinuation of biologic therapy for patients with severe asthma.

Asthma biologic use was not associated with an increase in respiratory infection risk, according to results from the 2026 ...

Please provide your email address to receive an email when new articles are posted on . Five factors were identified as reasons why patients avoid treatment with adalimumab and other biologics.

Earlier initiation of biologics in severe asthma could prevent thousands of deaths and save billions in healthcare costs by reducing exacerbations and healthcare resource utilization. Real-world data ...

Real-world data from 2016 to 2025 highlight the changing landscape of biologic use and the growing preference for tezepelumab in asthma.

Posters presented at the American Academy of Dermatology Annual Meeting identified significant undertreatment of psoriasis and significant gaps in biologic medication treatment. This content was ...

Please provide your email address to receive an email when new articles are posted on . Practices receive biologics directly and then bill the payer for their use. Advantages include improved ...

Smoking, higher body mass index (BMI), and previous exposure to biologics were linked to poorer responses to biologics among patients with psoriasis, in a meta-analysis. Older age (odds ratio [OR], ...

In a new study, researchers reviewed the advancements and ongoing challenges in the development of biologic therapies and disease prognosis of pediatric rheumatic diseases over the past 25 years, ...